Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its lead oncology candidate, ONC010, toward future clinical studies, according to a company announcement. ONC010 is a PNKP inhibitor designed to disrupt cancer cells' DNA repair mechanisms, potentially addressing treatment resistance in solid tumors.
The company recently completed kilogram-scale manufacturing of a key precursor used to produce ONC010's active pharmaceutical ingredient. This milestone supports future formulation development, Good Manufacturing Practice (GMP) production, and clinical studies. Additionally, Onco-Innovations signed a letter of intent with Nanosoft Polymers to collaborate on polymer development, drug delivery optimization, and formulation work.
Onco-Innovations has also engaged Nucro-Technics and Avance Clinical to support bioanalytical development and clinical and regulatory planning. These partnerships are part of the company's broader strategy to build the manufacturing, formulation, and clinical infrastructure needed to advance ONC010 toward first-in-human studies.
The company holds an exclusive worldwide license to patented technology targeting solid tumors. For more information, visit https://oncoinnovations.com/. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF.
This progress underscores Onco-Innovations' commitment to pioneering research in oncology and its efforts to bring innovative treatments to patients. The development of ONC010 represents a significant step in the fight against cancer, particularly for tumors that have developed resistance to existing therapies.
